Both HMGB1 and Ku proteins were previously thought to function as nuclear factors that bind DNA and enhance transcription. Genetic evidence reveals that loss of Ku proteins largely abrogates DNA double-stranded breaks (DSBs) repair and results in a severe defect in the development of B and T cells, whereas loss of HMGB1 leads to a phenotype of postnatal lethality with an unidentified reason. In addition, recent discoveries demonstrate that Ku70 is a mammalian receptor for Rickettsia conorii, and HMGB1 acts as a crucial cytokine that mediates the response to infection, injury and inflammation, thereby establishing a link between HMGB1 and Ku proteins as well as innate immunity. However, the biological functions of HMGB1 and Ku proteins in activation of the TLR pathway have not been explored. Moreover, recent findings have suggested that autoantibody/autoantigen/DNA complexes from the serum of SLE patients induce the pro-inflammatory and type I IFN response, which is involved in the immunopathogenesis of SLE in TLR9-dependent and independent manners. Intriguingly, both HMGB1 and Ku proteins are autoantigens of SLE, and autoantibodies against both of them are present in the serum of some SLE patients. Could HMGB1 and Ku proteins play a role in the antibody/antigen/DNA complex-mediated inflammatory and type I IFN response in SLE? Our results indicate that HMGB1 and Ku proteins are important for the pro-inflammatory cytokine and type I IFN response to immunostimulatory single-stranded DNA (ISS-DNA). However, details of molecular mechanisms are still missing. Thus, we have formulated three specific aims to elucidate the mechanism by which HMGB1 and Ku proteins are required for the innate immune response to ISS-DNA. We believe that our study will provide a better understanding of how HMGB1 and Ku autoantigens are involved in the cytokine response to DNAs, and how TLR9 is activated by ISS-DNA. Moreover, our study will reveal a link between the TLR9- dependent and -independent pathways. Finally, our study will provide new insight information on design of better adjuvants for vaccine against allergy, asthma, cancer and infectious diseases, while providing better inhibitors for treatment of SLE.

Public Health Relevance

Due to its powerful effects on inducing the Th1 response, CpG-DNA (ISS-DNA) has become a very attractive adjuvant in vaccine strategies against allergy, asthma, cancer and infectious disease. However, recent studies suggest that the autoantibody/autoantigen/DNA complex elicits the harmful inflammatory and type I IFN response in some autoimmune diseases including lupus. We identified that autoantigens such as DNA-PK and HMGB1 regulate the inflammatory and type I IFN response to CpG-DNA. To balance the benefits and side effects of CpG-DNA, we need to understand the molecular mechanisms by which DNAPK and HMGB1 activate the CpG- DNA pathway. We believe that our study will provide new insight information on design of better adjuvants for vaccine strategies against allergy, asthma, cancer and infectious disease, and provide better inhibitors for treatment of autoimmune diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI054128-08
Application #
8240074
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Palker, Thomas J
Project Start
2009-04-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
8
Fiscal Year
2012
Total Cost
$330,785
Indirect Cost
$110,262
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Li, Xianjing; Wang, Duowei; Chen, Zhen et al. (2015) G?i1 and G?i3 regulate macrophage polarization by forming a complex containing CD14 and Gab1. Proc Natl Acad Sci U S A 112:4731-6
Ma, Chi; Spies, Narrissa P; Gong, Ting et al. (2015) Involvement of DNA-PKcs in the type I IFN response to CpG-ODNs in conventional dendritic cells in TLR9-dependent or -independent manners. PLoS One 10:e0121371
Wang, Zhanwei; Dela Cruz, Rica; Ji, Fang et al. (2014) G(i)? proteins exhibit functional differences in the activation of ERK1/2, Akt and mTORC1 by growth factors in normal and breast cancer cells. Cell Commun Signal 12:10
Ma, Chi; Muranyi, Marianna; Chu, Catherine H et al. (2013) Involvement of DNA-PKcs in the IL-6 and IL-12 response to CpG-ODN is mediated by its interaction with TRAF6 in dendritic cells. PLoS One 8:e58072
Chu, Wen-Ming (2013) Tumor necrosis factor. Cancer Lett 328:222-5
Lee, Jongdae; Hayashi, Masaaki; Lo, Jeng-Fan et al. (2009) Nuclear factor kappaB (NF-kappaB) activation primes cells to a pro-inflammatory polarized response to a Toll-like receptor 7 (TLR7) agonist. Biochem J 421:301-10
Peng, Xiao; Zhang, Ping; Wang, Xin et al. (2007) Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha1. Ann N Y Acad Sci 1112:339-50
Ivanov, Stanimir; Dragoi, Ana-Maria; Wang, Xin et al. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970-81
Zhang, Ping; Chan, Justin; Dragoi, Ana-Maria et al. (2005) Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 6:531-7
Dragoi, Ana-Maria; Fu, Xiaoying; Ivanov, Stanimir et al. (2005) DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J 24:779-89